echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > A panoramic observation of imported new drugs approved by CFDA in 2017 (1)

    A panoramic observation of imported new drugs approved by CFDA in 2017 (1)

    • Last Update: 2018-03-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Based on the published data of CFDA / CDE, the new chemical drugs (NME / and its compound drugs) and biological drugs (BLA) were combined After searching on CFDA and CDE official websites, the author has determined that the following 40 imported varieties (see the table below) have been newly approved for listing by CFDA in 2017 Six of them are biological products or vaccines, and the rest are small molecule drugs or compound drugs The top multinational enterprises that have obtained CFDA approval are: Novartis, 6 varieties have been approved; Johnson & Johnson, 6 varieties have been approved; bringer Ingelheim, 5 varieties have been approved 40 imported varieties cover the following disease fields: anti-tumor or prevention, 9 items, including solid tumor and haematoma; type 2 diabetes, 6 items; hepatitis C, 6 items; central nervous system disease, 4 items; autoimmune disease, 4 items; anti hypertension or pulmonary hypertension, 3 items, etc After CFDA issued the opinions of the General Administration on solving the backlog of drug registration applications and implementing the priority review and approval in 2016, the speed of the listing of new drugs and generic drugs was significantly accelerated At present, CDE has released 25 batches of 423 varieties to be included in the priority review process (the previous batch 26 was not found) Many of the 40 varieties approved below are subject to priority review According to the priority evaluation of these drugs, the time difference between the time to market of Chinese imported innovative drugs and the time to market abroad was reduced to one year and five months (oxitinib, azd9291), followed by the time to market of Novartis' sakubatravalin sodium two years and one month later than that in the United States In addition, the food and drug administration has increased the number of reviewers, and the current CDE has increased from 150 to more than 800 The next section will comment on some of the 40 blockbuster drugs, especially those in great demand in the Chinese market Attachment: 40 imported new drugs approved by CFDA in 2017
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.